CytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques Oct 07, 2024 11:05am EDT
CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer Aug 12, 2024 8:30am EDT
CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024 Jun 27, 2024 8:30am EDT
